Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Chinese PLA General Hospital is the lead sponsor of 141 current clinical trials in our China register. 95 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Cyclophosphamide, Fludarabine and Chidamide. The most-studied condition is Hepatocellular Carcinoma.

ClinicalTrials.gov trials by status

Recruiting9567%
Not yet open3525%
Active, closed64%
By invitation54%

Trials by phase

Observational4532%
Not applicable2316%
Phase 1/22216%
Phase 22014%
Phase 1118%
Phase EARLY_PHASE1107%
Phase 454%
Phase 343%
Phase 2/311%

Clinical trials sponsored by Chinese PLA General Hospital

141 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. NCT06393361 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma Drugs: Chidamide, Decitabine	Phase 2	Recruiting	2024-06	China
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas NCT02259556 · ClinicalTrials.gov ↗ · Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma	Phase 1/2	Recruiting	2014-10	China
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma NCT07138547 · ClinicalTrials.gov ↗ · Lymphoma	Phase 1/2	Recruiting	2025-12	China
The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules NCT06340945 · ClinicalTrials.gov ↗ · Thyroid Nodules	Not applicable	Recruiting	2024-04	China
Correlation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy NCT03865914 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease	Observational	Recruiting	2017-11	China
Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma NCT06733740 · ClinicalTrials.gov ↗ · Papillary Thyroid Cancer	Observational	Recruiting	2024-12	China
Population PK-guided ATG Dosing in Haplo-HSCT NCT07791576 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplantation Drug: Anti Thymocyte Globulin	Phase 2	Recruiting	2025-05	China
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, First Line Therapy Drugs: Aclacinomycin, Azacytidine, Chidamide	Phase 2	Recruiting	2024-04	China
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer NCT06798376 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma	Observational	Recruiting	2025-01	China
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis NCT07045155 · ClinicalTrials.gov ↗ · Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease	Phase 4	Recruiting	2025-08	China
Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study NCT07724496 · ClinicalTrials.gov ↗ · Helicobacter Pylori, Early Gastric Cancer	Observational	Recruiting	2024-01	China
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma NCT06471738 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma Drugs: Rituximab, Venetoclax, Zanubrutinib	Phase 2	Recruiting	2024-07	China
Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations NCT07127185 · ClinicalTrials.gov ↗ · Ceftobiprole	Observational	Recruiting	2025-09	China
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study NCT07410039 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Attack Drugs: Eculizumab, IVIG, IVMP	Phase 4	Recruiting	2026-02	China
Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging NCT06817733 · ClinicalTrials.gov ↗ · Benign Prostatic Hyperplasia (BPH)	Not applicable	Recruiting	2025-04	China
Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU NCT07391618 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Recruiting	2025-05	China
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735 · ClinicalTrials.gov ↗ · Acute Lymphocytic Leukemia Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-02	China
The Evolution and Prognosis of Moyamoya Disease NCT05619068 · ClinicalTrials.gov ↗ · Moyamoya Disease, Revascularization, Cognitive Impairment	Observational	Recruiting	2022-09	China
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor NCT06883149 · ClinicalTrials.gov ↗ · Solid Tumor, Adult Drug: Anti-PD1	Phase 1	Recruiting	2025-03	China
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer NCT07822646 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: Nab-paclitaxel	Phase 3	Recruiting	2026-10	China
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors NCT05699811 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors Drugs: Abraxane, Camrelizumab, Cyclophosphamide	Phase 1/2	Recruiting	2023-02	China
7.0T Magnetic Resonance Imaging Study of Parkinson's Disease NCT06449404 · ClinicalTrials.gov ↗ · Parkinson's Diseases, MRI	Observational	Recruiting	2022-03	China
Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis NCT07724847 · ClinicalTrials.gov ↗ · Axial Spondyloarthritis (AxSpA), Spondyloarthritis (SpA), Chronic Back Pain	Observational	Recruiting	2026-04	China
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease NCT06969807 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease (DKD) Drug: Amimestrocel	Phase 2	Recruiting	2025-06	China
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma NCT07775508 · ClinicalTrials.gov ↗ · B-cell Lymphoma	Phase 1	Recruiting	2026-06	China
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA NCT07620275 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Ksvcbd	Phase 1	Recruiting	2026-09	China
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors NCT05681650 · ClinicalTrials.gov ↗ · HER2 Positive Advanced Solid Tumors Drugs: Albumin-Bound Paclitaxel, Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2023-10	China
Using Cardiac MRI to Predict Outcomes in Patients With STEMI NCT07072858 · ClinicalTrials.gov ↗ · Myocardial Infarction (MI), ST Segment Elevation Myocardial Infarction (STEMI), Magnetic Resonance Imaging (MRI)	Observational	Recruiting	2014-01	China
Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism NCT07557810 · ClinicalTrials.gov ↗ · Complication Rate, Efficacy and Safety, Hyperthyroidism/Thyrotoxicosis	Observational	Recruiting	2025-02	China
Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules NCT06733753 · ClinicalTrials.gov ↗ · Thyroid Nodule	Observational	Recruiting	2024-12	China
Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research NCT06559761 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Stage III	Observational	Recruiting	2023-01	China
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Drugs: Abraxane, Cyclophosphamide	Phase 1	Recruiting	2023-07	China
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer NCT07527026 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	2026-02	China
Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer NCT06733766 · ClinicalTrials.gov ↗ · Recurrent Thyroid Cancer	Observational	Recruiting	2024-12	China
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893 · ClinicalTrials.gov ↗ · nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma	Phase 2	Recruiting	2023-05	China
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma NCT07009002 · ClinicalTrials.gov ↗ · B Cell Lymphoma Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-06	China
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma NCT02851784 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Recruiting	2009-12	China
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy NCT05888909 · ClinicalTrials.gov ↗ · Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes	Observational	Recruiting	2022-08	China
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033 · ClinicalTrials.gov ↗ · Lymphoma	Phase 1/2	Recruiting	2023-07	China
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease NCT06203249 · ClinicalTrials.gov ↗ · Microbiome, Immune Function, Anti-MDA5 Antibody Positive Dermatomyositis	Observational	Recruiting	2024-01	China
Photon-Counting Cardiac CT in Post-PCI Patients NCT07763340 · ClinicalTrials.gov ↗ · Cardiovascular Diseases	Observational	Recruiting	2026-01	China
Effectiveness of OLE Airway Clearance Therapy in ICU Patients With Pulmonary Infections NCT07395297 · ClinicalTrials.gov ↗ · Pneumonia	Not applicable	Recruiting	2024-01	China
Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease NCT05677607 · ClinicalTrials.gov ↗ · ICAS - Intracranial Atherosclerosis, Cerebral Small Vessel Diseases	Observational	Recruiting	2023-01	China
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. NCT07044921 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic Drugs: Cetuximab, Irinotecan liposomes	Phase 2	Recruiting	2024-09	China
Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease NCT07094438 · ClinicalTrials.gov ↗ · Alzheimer Disease	Phase 1	Recruiting	2025-01	China
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury NCT06954740 · ClinicalTrials.gov ↗ · Acute Kidney Injury Drug: Amimestrocel	Phase 2	Recruiting	2025-06	China
VIM+PTT MRgFUS for PD NCT07044973 · ClinicalTrials.gov ↗ · Parkinson Disease	Not applicable	Recruiting	2025-07	China
Evaluation of the Effect of Pulmonary Rehabilitation on Patients With High Flow Oxygen Therapy NCT04441151 · ClinicalTrials.gov ↗ · Pulmonary Disease	Not applicable	Recruiting	2025-03	China
Thrombus Imaging and Treatment Analytics in Neurology NCT05663281 · ClinicalTrials.gov ↗ · Thrombus, Brain, Thrombosis	Observational	Recruiting	2022-12	China
Clinical Study of a Novel Sliding Compression Locking Plate in the Treatment of Fresh Femoral Neck Fractures NCT06713291 · ClinicalTrials.gov ↗ · Fracture of Femoral Neck	Not applicable	Recruiting	2024-12	China
Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke) NCT07635758 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Phase 1/2	Recruiting	2026-06	China
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis NCT07746180 · ClinicalTrials.gov ↗ · ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) Drug: Obinutuzumab beta	Phase 2	Recruiting	2026-08	China
Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer NCT04483076 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy Effect	Phase 3	Recruiting	2021-01	China
The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma NCT06316895 · ClinicalTrials.gov ↗ · Papillary Thyroid Cancer	Observational	Recruiting	2024-04	China
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. NCT06558773 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Eliglustat, Regorafenib	Phase 2	Recruiting	2026-03	China
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia NCT07512700 · ClinicalTrials.gov ↗ · Acute Monocytic Leukemia	Phase 2	Recruiting	2025-09	China
Effects of CI on Tinnitus and Its Symptoms NCT05453019 · ClinicalTrials.gov ↗ · Tinnitus	Not applicable	Recruiting	2022-07	China
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL NCT06014073 · ClinicalTrials.gov ↗ · Non Hodgkin's Lymphoma	Phase 1/2	Recruiting	2023-09	China
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma NCT07645690 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Clear Cell Renal Cell Carcinoma	Phase EARLY_PHASE1	Recruiting	2026-07	China
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma NCT06323525 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma	Phase 1/2	Recruiting	2024-04	China
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL NCT06838832 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma,B Cell Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-07	China
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL NCT06321289 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma,B Cell Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2024-03	China
Cold-Region Exposure and Cardiac Remodeling After PCI NCT07773870 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Percutaneous Coronary Intervention (PCI), Left Ventricular Remodeling	Observational	Recruiting	2026-06	China
Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patients With Carotid Artery Stenosis NCT07762664 · ClinicalTrials.gov ↗ · Carotid Artery Stenosis, Carotid Atherosclerosis, Carotid Atherosclerotic Plaque	Observational	Recruiting	2026-01	China
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection NCT06135922 · ClinicalTrials.gov ↗ · EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection	Phase 1	Recruiting	2023-08	China
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL NCT05554939 · ClinicalTrials.gov ↗ · Non Hodgkin's Lymphoma	Phase 1/2	Recruiting	2022-12	China
Hydration Guided by Remote Dielectric Sensing (ReDS) System for Preventing Acute Kidney Injury in Elderly Patients With Renal Insufficiency for Coronary Angiography and Intervention NCT07394959 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Chronic Kidney Disease, Elderly	Not applicable	Recruiting	2024-09	China
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA NCT07620314 · ClinicalTrials.gov ↗ · Non-Hodgkin's Lymphoma	Phase 1	Recruiting	2026-07	China
Deep Enhanced Imaging in Stroke and Vascular Neurology NCT05614193 · ClinicalTrials.gov ↗ · Radiology, Cerebral Stroke, Vascular Diseases	Observational	Recruiting	2022-12	China
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy NCT05839314 · ClinicalTrials.gov ↗ · Nephropathy, Glomerular Diseases, Idiopathic Membranous Nephropathy Drug: Huaier	Phase 4	Recruiting	2023-05	China
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer Drugs: Camrelizumab, Gemcitabine, Nab-paclitaxel	Phase 1/2	Recruiting	2021-08	China
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT06084819 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia Drugs: Aclacinomycin, Azacytidine, Chidamide	Phase 2	Recruiting	2023-08	China
Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community NCT06352736 · ClinicalTrials.gov ↗ · Lower Urinary Tract Symptoms	Observational	Recruiting	2023-06	China
Comparative Study of Prognosis and QOL Between APD-RPM and CAPD NCT05738525 · ClinicalTrials.gov ↗ · End-stage Renal Disease	Observational	Recruiting	2023-06	China
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease NCT07148791 · ClinicalTrials.gov ↗ · IgG4 Related Disease, B-cell Mediated Autoimmune Disorders	Phase 2	Recruiting	2025-09	China
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER) NCT07089303 · ClinicalTrials.gov ↗ · Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease	Observational	Recruiting	2025-07	China
Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules NCT06729762 · ClinicalTrials.gov ↗ · Thyroid Nodule (Benign)	Observational	Recruiting	2024-12	China
To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma NCT04365751 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2019-12	China
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen NCT05088226 · ClinicalTrials.gov ↗ · Peripheral Blood Stem Cell Transplantation Drugs: Chidamide, Ruxolitinib	Phase 2	Recruiting	2021-12	China
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. NCT07570563 · ClinicalTrials.gov ↗ · Hematologic Malignancy, Solid Tumor Drugs: Albumin paclitaxel, Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2026-06	China
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial NCT07212933 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy Drug: Trifluridine/Tipiracil	Phase 2	Recruiting	2025-07	China
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors NCT05947487 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1/2	Recruiting	2023-07	China
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT NCT06119256 · ClinicalTrials.gov ↗ · EBV Infection After Allogenic HSCT	Phase 1	Recruiting	2023-08	China
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma NCT07018518 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Adult Drug: Anti-PD1	Phase 1	Recruiting	2025-06	China
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma NCT07067905 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma and Glioblastoma	Phase EARLY_PHASE1	Recruiting	2025-06	China
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma NCT06462742 · ClinicalTrials.gov ↗ · Overall Survival, Disease-free Survival	Observational	Recruiting	2009-01	China
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia NCT07514936 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients Drugs: Aclacinomycin, Azacytidine, Chidamide	Phase 3	Recruiting	2024-11	China
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial NCT07101588 · ClinicalTrials.gov ↗ · Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Phase 4	Recruiting	2025-01	China
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2 NCT05403242 · ClinicalTrials.gov ↗ · Advanced Gastroesophageal Adenocarcinoma Drugs: Disitamab Vedotin, Tegafur Gimeracil Oteracil	Phase 1/2	Recruiting	2022-09	China
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy NCT06843304 · ClinicalTrials.gov ↗ · Diabetic Nephropathy, T2DM	Observational	Recruiting	2024-01	China
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy. NCT07585981 · ClinicalTrials.gov ↗ · IgA Glomerulonephritis	Observational	Recruiting	2025-10	China
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors NCT05693844 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors Drugs: Albumin-Bound Paclitaxel, Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2023-01	China
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885 · ClinicalTrials.gov ↗ · Acute Lymphocytic Leukemia Drugs: Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-06	China
ATG Individualized Dosing Model in URD-PBSCT. NCT06572462 · ClinicalTrials.gov ↗ · Cytomegalovirus Infections, Infection Reactivation, Stem Cell Transplant Complications	Phase 2	Recruiting	2020-12	China
Clinical Application of Wearable Ultrasound Sensors NCT07009873 · ClinicalTrials.gov ↗ · DVT - Deep Vein Thrombosis, POCUS	Observational	Recruiting	2025-08	China
Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia NCT07608640 · Age-related Hearing Loss, Dementia	Observational	Not yet open	2026-05	China
Chinese, Overweight or Obesity, Real-World Registry Study NCT07525037 · ClinicalTrials.gov ↗ · Obesity Type 2 Diabetes Mellitus	Observational	Not yet open	2026-05	China
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder. NCT07592754 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disease (NMOSD) Drug: Ksvcbd	Phase EARLY_PHASE1	Not yet open	2026-05	China
Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia NCT07612605 · ClinicalTrials.gov ↗ · Pneumonia Drug: Bacteriophage	Phase EARLY_PHASE1	Not yet open	2026-06	China
A Study of CAR-T Cells in Subjects With Autoimmune Diseases NCT07040917 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase EARLY_PHASE1	Not yet open	2025-09	China

Showing the 100 most recently updated of 141 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Chinese PLA General Hospital trials

45 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 5 more in the trial list above.

Conditions in Chinese PLA General Hospital trials

202 conditions

Hepatocellular Carcinoma4 Lymphoma3 Solid Tumor3 Adult3 Depression3 Anxiety3 Solid Tumor, Adult3 Coronary Artery Disease3Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma2Non-Hodgkin's Lymphoma2 Diabetic Kidney Disease2Papillary Thyroid Cancer2Pneumonia2 Autoimmune Diseases2Acute Lymphocytic Leukemia2Colorectal Cancer2Fracture of Neck of Femur2MRI2Postoperative2EphA2 Overexpression2Alzheimer Disease2 Acute Kidney Injury2 Non Hodgkin's Lymphoma2Non-hodgkin Lymphoma,B Cell2

By trial register

Register	Trials	Recruiting
Clinical trials in China	141	95

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Hepatocellular Carcinoma

Sponsor	Trials
Sun Yat-sen University	23
The First Affiliated Hospital with Nanjing Medical University	4
Akeso	3
Fujian Provincial Hospital	3
Shanghai Junshi Bioscience	3
Zhongda Hospital	3
Guangxi Medical University	3
Replimune	2
HistoSonics	2
Teclison	2

Sponsors with the most current trials registered for this condition.

Questions about Chinese PLA General Hospital trials

How many clinical trials does Chinese PLA General Hospital sponsor?

Chinese PLA General Hospital is the lead sponsor of 141 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chinese PLA General Hospital trials recruiting?

Yes. 95 of its 141 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chinese PLA General Hospital testing?

Its current trials name 45 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (12), Fludarabine (9), Chidamide (6), Venetoclax (4) and Abraxane (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Chinese PLA General Hospital clinical trials